Article Details

FDA Grants Breakthrough Therapy Designation to Inavolisib for PIK3CA-Mutated Breast Cancer

Retrieved on: 2024-05-21 20:36:23

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Breakthrough Therapy Designation to Inavolisib for PIK3CA-Mutated Breast Cancer. View article details on hiswai:

Excerpt

... monoclonal antibody, BsAb5003, and evaluated its efficacy against multiple myeloma. ... Bispecific antibodies are monoclonal antibodies with 2 binding ...

Article found on: www.pharmacytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo